Dupilumab for the treatment of adult atopic dermatitis in special populations.

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-19 DOI:10.1080/09546634.2022.2102121

Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano

{"title":"Dupilumab for the treatment of adult atopic dermatitis in special populations.","authors":"Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano","doi":"10.1080/09546634.2022.2102121","DOIUrl":null,"url":null,"abstract":"Background: Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.Objectives: To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs versus not-SPs.Methods: A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.Results: A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (p < .0001), without significant differences between the groups. No differences were recorded for safety.Conclusions: There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3028-3033"},"PeriodicalIF":2.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2102121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 16

Abstract

Background: Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.

Objectives: To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs versus not-SPs.

Methods: A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.

Results: A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (p < .0001), without significant differences between the groups. No differences were recorded for safety.

Conclusions: There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.

查看原文本刊更多论文

Dupilumab用于治疗特殊人群的成人特应性皮炎。

背景:特殊人群(SPs)是指在临床研究中需要额外考虑的人群。与非SPs相比，SPs的治疗效果或副作用的发生可能不同。目的:回顾性比较dupilumab治疗SPs与非SPs的有效性和安全性。方法:一项为期52周的回顾性研究纳入了诊断为中度至重度AD并接受标记剂量dupilumab治疗的患者。患者分为A组(SPs患者)和B组(非SPs患者)。采用湿疹区域严重程度指数(EASI)、瘙痒数值评定量表(P-NRS)和皮肤病生活质量指数(DLQI)评分在基线和4周后(W4)、W16、W24和W52进行疾病严重程度评估。结果:共纳入263例患者，分为A组(25例)和B组(238例)。SPs包括癌症史、严重肾衰竭、病毒性肝炎、神经系统疾病、获得性免疫缺陷综合征和移植患者。在每次随访时，两组的EASI、DLQI和p - nrs均有统计学意义的降低(p)。结论:sp组与非sp组在dupilumab治疗AD的有效性和安全性方面无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.